Patents by Inventor Annika Mayra
Annika Mayra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10087480Abstract: The invention is based on a correlation observed between serotonin level and intestinal flora. The invention relates to a relative proportion of bifidobacteria in the intestine and in particular to a product increasing the ratio of bifidobacteria to Clostridia, to be used for raising the serotonin level. The invention also relates to a method for estimating a health risk associated with serotonin depletion by determining a relative proportion between bifidobacteria or Clostridia in the intestine or their ratio to one another. The invention further relates to a method for selecting a form of therapy for raising the serotonin level by determining a relative proportion between bifidobacteria or Clostridia in the intestine or their ratio to one another.Type: GrantFiled: October 12, 2012Date of Patent: October 2, 2018Assignee: Gut Guide OyInventors: Annika Mayra-Makinen, Eveliina Munukka
-
Patent number: 10000818Abstract: The invention is based on a correlation observed between visceral fat and gut flora. The invention relates to a product increasing the relative proportion of bifidobacteria in the intestines and to be used for preventing formation of visceral fat or for reducing the amount thereof in the body. In particular, the product increases the ratio of bifidobacteria to Clostridia. The invention also relates to determining visceral fat in the body by determining the relative proportion of bifidobacteria or Clostridia or their ratio to each other in the intestines. The invention further relates to a method for estimating, in the same manner, the health risk associated with obesity.Type: GrantFiled: October 12, 2012Date of Patent: June 19, 2018Assignee: Gut Guide OyInventors: Annika Mayra-Makinen, Eveliina Munukka
-
Publication number: 20170095517Abstract: The present invention relates to the field of medicine and in particular to celiac disease (CD). Specifically the present invention relates to methods and means for detection of CD using novel microbiomarker, celiac gut index (CGI). The invention relates also to methods and means for treatment or prophylaxis of CD. The present invention provides a novel product comprising a gut microbiome altering agent that, when administered to an individual, improves the state of health of individuals suffering or susceptible to suffer from celiac disease and possibly reduces the likelihood of acquiring celiac disease. The product of the invention provides a natural and safe manner for the treatment of celiac disease. The present invention provides also a novel method for aiding diagnosis of CD by the specific gut health biomarker, Celiac Gut Index (GCI).Type: ApplicationFiled: June 10, 2015Publication date: April 6, 2017Inventors: Annika Mayra, Eveliina Munukka
-
Publication number: 20140301995Abstract: The invention is based on a correlation observed between serotonin level and intestinal flora. The invention relates to a relative proportion of bifidobacteria in the intestine and in particular to a product increasing the ratio of bifidobacteria to Clostridia, to be used for raising the serotonin level. The invention also relates to a method for estimating a health risk associated with serotonin depletion by determining a relative proportion between bifidobacteria or Clostridia in the intestine or their ratio to one another. The invention further relates to a method for selecting a form of therapy for raising the serotonin level by determining a relative proportion between bifidobacteria or Clostridia in the intestine or their ratio to one another.Type: ApplicationFiled: October 12, 2012Publication date: October 9, 2014Inventors: Annika Mayra-Makinen, Eveliina Munukka
-
Publication number: 20140286920Abstract: The invention is based on a correlation observed between visceral fat and gut flora. The invention relates to a product increasing the relative proportion of bifidobacteria in the intestines and to be used for preventing formation of visceral fat or for reducing the amount thereof in the body. In particular, the product increases the ratio of bifidobacteria to Clostridia. The invention also relates to determining visceral fat in the body by determining the relative proportion of bifidobacteria or Clostridia or their ratio to each other in the intestines. The invention further relates to a method for estimating, in the same manner, the health risk associated with obesity.Type: ApplicationFiled: October 12, 2012Publication date: September 25, 2014Applicant: Gut Guide OyInventors: Annika Mayra-Makinen, Eveliina Munukka
-
Patent number: 8309073Abstract: The invention relates to a probiotic combination comprising different combinations of lactobacilli, propionic acid bacteria and/or bifidobacteria. The probiotics are preferably combined with a suitable prebiotic to form a synbiotic. The combination of the invention can be consumed as such or combined with a suitable foodstuff or pharmaceutical product, and it is therapeutically useful for example for stimulating the immune system and for general health improvement.Type: GrantFiled: January 17, 2002Date of Patent: November 13, 2012Assignee: Valio Ltd.Inventors: Annika Mäyrä-Mäkinen, Tarja Suomalainen, Outi Vaarala
-
Publication number: 20050271640Abstract: The invention relates to the use of microbes Lactobacillus rhamnosus LGG, ATCC 53103, Latobacillus rhamnosus LC705, DSM 7061, and Propionibacterium freudenreichii ssp. shermanii PJS, DSM 7067 in inhibiting yeast growth, for preventing and treating diseases caused by yeast and for relieving yeast-related symptoms in animals or humans.Type: ApplicationFiled: November 3, 2003Publication date: December 8, 2005Inventors: Tarja Suomalainen, Annika Mayra-Makinen
-
Patent number: 6972282Abstract: The invention relates to a process for preparing a product containing antihypertensive peptides by fermenting a casein-containing starting material with lactic acid bacteria. The invention also relates to the obtained product and its use as a functional product as such or as an ingredient or additive of edible substances.Type: GrantFiled: October 30, 2000Date of Patent: December 6, 2005Assignee: Valio Ltd.Inventors: Olli Tossavainen, Tarja Suomalainen, Janne Sahlstein, Annika Mäyrä-Mäkinen
-
Patent number: 6960456Abstract: The invention relates to a method for preparing conjugated linoleic acid and particularly its cis-9,trans-11 isomer from linoleic acid by fermentation. The invention also relates to products prepared by the method.Type: GrantFiled: November 16, 2000Date of Patent: November 1, 2005Assignee: Valio Ltd.Inventors: Simo Laakso, Auli Rainio, Marjatta Vahvaselka, Annika Mäyrä-Mäkinen, Soile Tynkkynen, Tarja Suomalainen
-
Patent number: 6890529Abstract: The invention relates to a new strain, Lactobacillus helveticus LBK-16 H, DSM 13137, and a bacterial preparation containing the same. The new strain Lactobacillus helveticus LBK-16 H has proteolytic activity and is capable of promoting the production of nitric oxide, and thus it is useful both as a starter bacterium in dairy industry and as a therapeutic substance as such and in various health-promoting products and pharmaceuticals.Type: GrantFiled: October 30, 2000Date of Patent: May 10, 2005Assignee: Valio LTDInventors: Annika Mäyrä-Mäkinen, Tarja Suomalainen
-
Publication number: 20040062758Abstract: The invention relates to a probiotic combination comprising different combinations of lactobacilli. propionic acid bacteria and/or bifidobacteria. The probiotics are preferably combined with a suitable prebiotic to form a synbiotic. The combination of the invention can be consumed as such or combined with a suitable foodstuff or pharmaceutical product, and it is therapeutically useful for example for stimulating the immune system and for general health improvement.Type: ApplicationFiled: October 22, 2003Publication date: April 1, 2004Inventors: Annika Mayra-Makinen, Tarja Suomalainen, Outi Vaarala
-
Patent number: 5908646Abstract: The invention relates to inhibition of clostridia with lactic acid bacteria. In particular, the invention relates to the use of Lactobacillus rhamnosus in the food industry to inhibit the growth and activity of clostridia. Preferred embodiments of the invention include the use of Lactobacillus rhamnosus in prevention of butyric acid fermentation and in cheese production.Type: GrantFiled: December 20, 1996Date of Patent: June 1, 1999Assignee: Valio OyInventors: Annika Mayra-Makinen, Tarja Suomalainen
-
Patent number: 5658748Abstract: The invention relates to new Streptococcus thermophilus strains containing genes giving the bioluminescence property. The strains can be applied widely for analytical purposes, e.g. in the determination of bacteriophages and antibiotics, especially from liquid samples. The invention also relates to a test set containing a bioluminescent Streptococcus thermophilus strain, and to processes for the determination of bacteriophages or antibiotics from a liquid sample.Type: GrantFiled: August 16, 1994Date of Patent: August 19, 1997Assignee: Valio OyInventors: Annika Mayra-Makinen, Mervi Sibakov, Soile Tynkkynen
-
Patent number: 5378458Abstract: The invention relates to a novel microorganism strain Lactobacillus casei ssp. rhamnosus LC-705, DSM 7061, having a yeast and mold controlling effect, to bacterial preparations comprising this strain, alone or in combination with a bacterium of the genus Propionibacterium or another strain of the bacterium Lactobacillus casei and/or with conventional agents used for yeast and mold control. The invention also relates to the use of said strain and said bacterial preparations for yeast and mold control and to a method for controlling the growth of yeasts and molds using a bacterial preparation comprising said strain.Type: GrantFiled: September 30, 1993Date of Patent: January 3, 1995Assignee: Valio Meijerien Keskusosuusliike, Valio Ltd.Inventors: Annika Mayra-Makinen, Tarja Suomalainen
-
Patent number: 4929546Abstract: A test set comprising a purified culture of Streptococcus thermophilus T101 concentrate and a water-based protective agent in dilution ratio of about 4 to 5.times.10.sup.-2. The test set may also advantageously comprise an indicator. The test method includes the steps of incubating the test set and evaluating the color. The present invention also comprises a purified culture of Streptococcus thermophilus T101 strain.Type: GrantFiled: April 6, 1988Date of Patent: May 29, 1990Assignee: Valio Meijerien KeskusosuusliikeInventor: Annika Mayra-Makinen